Study collaborators at the NIH's National Institute of Allergy and Infectious Diseases (NIAID) found that treatment with mAb 3A6 can benefit non-human primates in advanced stages of Ebola virus ...

The National Institutes of Health's initial trial found the experimental vaccine for the Ebola virus so far is safe for humans and produced an immune response. Researches found anti-Ebola ...

New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus ...

Ebola is spread by contact with the bodily fluids of an infected person or contaminated materials. Symptoms include fever, vomiting, diarrhea, muscle pain and at times internal and external bleeding.

Study collaborators at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) found that treatment with mAb 3A6 can benefit non-human primates in advanced stages of Ebola virus ...